Aim: To explore the anti-lymphoma efficacy of ZnPcS(2)P(2)-mediated photodynamic therapy(PDT) combined with mGM-CSF and mB7.1 gene-modified high-tumorigenicity lymphoma cells (EL-4 cells) in C57BL/6 mice.
Methods: EL-4/pLXSN, EL-4/GM and EL-4/B7 were generated by consecutive infection of EL-4 cells with respective retroviruses, i.e pLXSN, pLXSNmGM-CSF and pLXSNmB7.1. The total of 40 C57BL/6 mice receiving the inoculation of EL-4 cells five days before the experiment, were randomly divided into five groups with 8 in each group: control group (without any treatment), ZnPc-PDT control group, ZnPc-PDT+EL-4/pLXSN control group, EL-4/B7+EL-4/GM control group and ZnPc-PDT+EL-4/B7+EL-4/GM group. The procedure of PDT was carried out as follows: the mice were injected with ZnPcS(2)P(2) via the lateral tail veins, and 4 h later the tumor was irradiated with 670 nm laser. The size of tumor node was measured every other day. The survival time and relative tumor volume(RTV) of each group were compared. The histological morphology of tumor was observed.
Results: Compared with each control group, the survival time of experimental group was significantly prolonged (P<0.01). Moreover, difference of the survival time was measured between ZnPc-PDT control group and EL-4/B7+EL-4/GM control group (P=0.01).
Conclusion: Tumor-localized immune stimulation by mGM-CSF and mB7.1 remarkably enhanced ZnPc-PDT-elicited anti-lymphoma potency.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents.
Hum Vaccin Immunother
December 2025
Research and Development, Infectious Disease, Moderna, Inc., Cambridge, MA, USA.
Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12-17 years), with and without pre-booster SARS-CoV-2 infection. Participants who had received the 2-dose mRNA-1273 100-µg primary series in the TeenCOVE trial (NCT04649151) were offered the mRNA-1273 50-μg booster. Primary objectives included safety and inference of effectiveness by establishing noninferiority of neutralizing antibody (nAb) responses after the booster compared with the nAb post-primary series of mRNA-1273 among young adults in COVE (NCT04470427).
View Article and Find Full Text PDFMindfulness Training vs Recovery Support for Opioid Use, Craving, and Anxiety During Buprenorphine Treatment: A Randomized Clinical Trial.
JAMA Netw Open
January 2025
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.
Importance: During buprenorphine treatment for opioid use disorder (OUD), risk factors for opioid relapse or treatment dropout include comorbid substance use disorder, anxiety, or residual opioid craving. There is a need for a well-powered trial to evaluate virtually delivered groups, including both mindfulness and evidence-based approaches, to address these comorbidities during buprenorphine treatment.
Objective: To compare the effects of the Mindful Recovery Opioid Use Disorder Care Continuum (M-ROCC) vs active control among adults receiving buprenorphine for OUD.
Perfusion Capacity as a Predictive Index for Assessing Visual Functional Recovery in Patients With Idiopathic Epiretinal Membrane.
Transl Vis Sci Technol
January 2025
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.
Purpose: This study investigates the association between visual function and retinal vasculature metrics, particularly perfusion capacity (PC), in eyes with idiopathic epiretinal membrane (iERM), using optical coherence tomography angiography (OCTA).
Methods: This retrospective study includes 30 eyes from 30 iERM patients who had surgery, with a three-month follow-up period. In addition, 28 eyes from 28 healthy individuals served as a control group.
Safety of Human USH1C Transgene Expression Following Subretinal Injection in Wild-Type Pigs.
Invest Ophthalmol Vis Sci
January 2025
Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Purpose: This study aimed to evaluate early-phase safety of subretinal application of AAVanc80.CAG.USH1Ca1 (OT_USH_101) in wild-type (WT) pigs, examining the effects of a vehicle control, low dose, and high dose.
View Article and Find Full Text PDFMontelukast Use and the Risk of Neuropsychiatric Adverse Events in Children.
JAMA Pediatr
January 2025
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Importance: Spontaneous reports have indicated that montelukast increases the risk of neuropsychiatric adverse events, and the US Food and Drug Administration added a boxed warning about these risks in 2020. However, the potential mechanism is not well understood, and the observational evidence is scarce, particularly in children.
Objective: To assess the potential association between the use of montelukast and the risk of neuropsychiatric adverse events in children and adolescents.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!